Freenome (FRNM) Q3 2026 earnings review
Freenome wins colon test approval, but Q4 sales drop back
Freenome, a developer of blood tests for early cancer detection, turned a one-time profit in its debut public quarter as US regulators approved its colorectal screen. That approval unlocked $180 million in license revenue and a $100 million cash payment from commercial partner Abbott. Chief executive Aaron Elliott also raised $310 million from the July listing, but the full-year plan leaves just $3 million in fourth-quarter sales by our math.
| Revenue | $183.5M $180M from FDA approval milestone recognition |
|---|---|
| Free cash flow | $35.7M -$44.8M a year ago |
| Cash and marketable securities | $430.0M $216.7M at the end of 2025 |
| Full-year 2026 revenue outlook | $192–194M leaves ~$3M for Q4 by our math |
⚖️ Verdict: 🟢 Bullish
The story got better because the company cleared its biggest regulatory hurdle, launched two screening tests, and wiped out its convertible debt. It now holds $430 million in cash and securities to fund its pipeline. One caution: the third-quarter profit was a one-off accounting event, and operating expenses still exceeded $71 million even after stripping out stock-based pay.
The question now is how quickly commercial test orders from Abbott's colorectal rollout and Freenome's new lung test can replace one-time milestone payments. If doctors adopt the blood tests fast, recurring revenue will trim the quarterly cash burn; if insurance coverage takes time, laboratory spending will steadily drain the new cash pile. The initial 2027 revenue outlook next quarter will tell.
🐂 Bull Case
FDA Approval Unlocked $180 Million and a Commercial Launch
Freenome develops blood tests that use artificial intelligence and molecular data to spot cancer early. On July 24, US regulators approved SimpleScreen CRC, its blood test "for adults 45 and older at average risk for colorectal cancer". That approval triggered a $100 million payment from commercial partner Abbott and allowed the diagnostics company to book $180.0 million in license and collaboration revenue during the third quarter.
Abbott launched the colorectal test across the United States on September 30, the final day of the quarter. Freenome also reported study results for an updated version of the test, which met all primary and secondary goals and improved the detection of advanced precancerous growths. Moving from clinical trials to a partner-backed product gives the business its first commercial engine.
What to watch: fourth-quarter collaboration revenue from Abbott's rollout, which arrives with full-year results. It will show how fast doctor orders turn into ongoing royalties now that the one-time approval payment is behind it.
Public Debut and Note Conversions Leave $430 Million in Cash
"Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation," chief executive Aaron Elliott said. The cancer test maker listed on the Nasdaq in July, raising $310 million in gross proceeds, and collected its $100 million regulatory milestone in the same period.
- Cash and marketable securities: $430.0 million, up from $216.7 million at the end of 2025
- Abbott convertible note: $50.5 million converted into 3.4 million shares at $15.00 each
- Roche convertible note: converted into 6.4 million shares at $12.00 each upon the July listing
- Remaining convertible debt on the balance sheet: zero, down from $102.5 million at year-end
Clearing both convertible notes removes $102.5 million in debt liabilities while the new cash funds the next wave of clinical trials. What to watch: quarterly cash burn in the fourth quarter, when no large regulatory payment is scheduled to offset laboratory spending.
Lung Test Launch and Breakthrough Status Expand the Pipeline
In October, after the quarter closed, the blood-test developer launched SimpleScreen Lung, a protein-based laboratory test "for adults ages 50 to 80 with a significant smoking history who are not currently participating in guideline-recommended screening". Doctors can order the new lung screen alongside the colorectal test using a single blood draw for patients eligible for both.
US regulators also granted Breakthrough Device Designation for a next-generation version of the lung test that analyzes multiple molecular markers. That status can speed up regulatory review. What to watch: clinical readouts for the next two single-cancer tests expected in December, which will show whether the discovery platform works beyond colon and lung cancer.
🐻 Bear Case
The Full-Year Plan Points to Just $3 Million in Q4 Sales
Elliott highlighted the company's commercial momentum after revenue reached $183.5 million in the third quarter and $190.0 million over the first nine months of 2026. Yet Freenome's own full-year outlook calls for $192 million to $194 million in total revenue.
By our math, subtracting the nine-month total from the $193 million middle of the range leaves just $3.0 million in revenue for the fourth quarter, a 98% drop from the third quarter. Even though the fourth quarter reflects "contributions from license and collaboration agreements, research and development services, and early commercial activities", the implied figure shows that Abbott's September 30 colorectal launch and Freenome's October lung launch will contribute very little revenue this year.
What to watch: the initial 2027 revenue outlook, which arrives with fourth-quarter results. A low target would mean commercial adoption and insurance coverage are taking longer to build than the headline launch suggests.
Underlying Cash Burn Continues Outside the One-Time Milestone
The third-quarter profit of $60.1 million and free cash flow of $35.7 million rested entirely on the $180.0 million accounting recognition and $100 million milestone from the colorectal test approval. Operating costs rose to $113.5 million from $66.3 million a year ago, "primarily driven by transaction and stock-based compensation costs related to the closing of the business combination".
- Research and development (laboratory and trial costs): $68.4 million, or 37.3% of revenue, up 35.1% from a year ago
- General and administrative (overhead and listing costs): $44.6 million, or 24.3% of revenue, up 196.4% from a year ago
- Stock-based compensation: $41.9 million, up from $2.8 million a year ago
- First-half free cash flow: negative $109.6 million by our math, bringing the nine-month total to negative $73.9 million
Even excluding $41.9 million in stock-based pay, cash operating expenses ran above $71 million in the quarter. Because fourth-quarter revenue will drop to about $3 million by our math, the business will return to heavy losses immediately. What to watch: general and administrative spending in the fourth quarter, to see how much overhead drops away after the one-time listing costs clear.
👓 Other Themes
Listing and Debt Conversions Expanded the Share Count by 63%
Going public and wiping out convertible debt came with substantial dilution for earlier holders. Common shares issued and outstanding rose 63.2% from 67.9 million at the end of 2025 to 110.9 million on September 30, 2026, including 9.8 million shares issued to Abbott and Roche upon note conversion. Future per-share profits will be spread across this much larger base.
💲 Other KPIs
Total deferred revenue — cash partners have paid upfront for work or licenses not yet recognized — fell 56.3% from $56.3 million at the end of 2025 to $24.6 million. The current portion dropped from $7.1 million to zero as Freenome recognized collaboration revenue upon receiving FDA approval.
Revenue from research services fell 9.0% from a year ago in the third quarter, to $0.9 million from $1.0 million. Over the first nine months of 2026, service sales declined 9.8% to $2.3 million, leaving the business reliant on licensing milestones until commercial test sales scale up.
Uncollected customer billings rose to $8.8 million at the end of September from $1.3 million at the end of 2025. The $7.5 million increase absorbed a portion of working capital during the quarter as partner billing ramped up alongside the colorectal test approval.
🔮 Guidance
New. The cancer test maker issued its first public full-year plan, calling for $193 million at the middle of the range. With $190.0 million already booked in the first nine months, the plan leaves $2.0 million to $4.0 million ($3.0 million at the middle) for the fourth quarter by our math, down 98% from the third quarter after the one-time approval recognition.
❓ Key Questions
What are the royalty rates on Abbott's colorectal test sales?
Abbott launched SimpleScreen CRC on September 30 under an exclusive US license. Without the royalty percentage or commercial milestone schedule, investors cannot calculate how many tests Abbott must sell to cover Freenome's $68 million quarterly research budget.
How much of the $44.6 million G&A bill was one-time?
General and administrative expenses nearly tripled from a year ago due to listing transaction fees and stock-based pay. Management did not separate the one-time deal fees from ongoing public-company overhead.
Which cancers are in the two December clinical readouts?
The company promised two single-cancer study readouts in December and a multi-cancer readout in mid-2027, but did not name the two cancer types or the trial sizes in the release.
How will SimpleScreen Lung be priced and reimbursed before FDA approval?
Freenome launched SimpleScreen Lung in October as a laboratory-developed test while it works on an FDA-reviewed version. The release gives no pricing, insurance coverage status, or sales force size for this self-commercialized test.